-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Iovance Biotherapeutics, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2023 to Q1 2024.
- Iovance Biotherapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$1.41M.
Deferred Income Tax Expense (Benefit), Quarterly (USD)